2. Academic Validation
  3. BNIPL is a promising biomarker of laryngeal cancer: novel insights from bioinformatics analysis and experimental validation

BNIPL is a promising biomarker of laryngeal cancer: novel insights from bioinformatics analysis and experimental validation

  • BMC Med Genomics. 2024 Feb 1;17(1):45. doi: 10.1186/s12920-024-01811-z.
Rui Wang 1 2,  Ying Gao 1 2,  Shuxin Wen 3 4,  Xiudong Guo 2 5
Affiliations

Affiliations

  • 1 Department of Otolaryngology Head and Neck Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99, Longcheng Street, Taiyuan City, Shanxi Province, 030032, China.
  • 2 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Hubei Province, 430030, China.
  • 3 Department of Otolaryngology Head and Neck Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99, Longcheng Street, Taiyuan City, Shanxi Province, 030032, China. [email protected].
  • 4 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Hubei Province, 430030, China. [email protected].
  • 5 Department of Head Neck and Breast Oncology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan City, Shanxi Province, 030032, China.
PMID: 38302910 DOI: 10.1186/s12920-024-01811-z
Abstract

Background: Laryngeal Cancer (LC) is a malignant tumor with high incidence and mortality. We aim to explore key genes as novel biomarkers to find potential target of LC in clinic diagnosis and treatment.

Methods: We retrieved GSE143224 and GSE84957 datasets from the Gene Expression Omnibus database to screen the differentially expressed genes (DEGs). Hub genes were identified from protein-protein interaction networks and further determined using receiver operating characteristic curves and principal component analysis. The expression of hub gene was verified by quantitative real time polymerase chain reaction. The transfection efficiency of BCL2 interacting protein like (BNIPL) was measured by western blot. Proliferation, migration, and invasion abilities were detected by Cell Counting Kit-8, wound-healing, and transwell assays, respectively.

Results: Total 96 overlapping DEGs were screened out from GSE143224 and GSE84957 datasets. Six hub genes (BNIPL, KRT4, IGFBP3, MMP10, MMP3, and TGFBI) were identified from PPI network. BNIPL was selected as the target gene. The receiver operating characteristic curves of BNIPL suggested that the false positive rate was 18.5% and the true positive rate was 81.5%, showing high predictive values for LC. The expression level of BNIPL was downregulated in TU212 and TU686 cells. Additionally, overexpression of BNIPL suppressed the proliferation, migration, and invasion of TU212 and TU686 cells.

Conclusion: BNIPL is a novel gene signature involved in LC progression, which exerts an inhibitory effect on LC development. These findings provide a novel insight into the pathogenesis of LC.

Keywords

BNIPL; DEGs; Hub gene; Laryngeal cancer.

Figures
Products